Gemcitabine
- Generic Name
- Gemcitabine
- Brand Names
- Gemzar
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11F2N3O4
- CAS Number
- 95058-81-4
- Unique Ingredient Identifier
- B76N6SBZ8R
- Background
Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...
- Indication
Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.
In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...
- Associated Conditions
- Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
- Associated Therapies
- -
Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06196788
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies
- Conditions
- Interventions
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2024-04-30
- Target Recruit Count
- 35
- Registration Number
- NCT06181032
- Locations
- 🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 30
- Registration Number
- NCT06177522
- Locations
- 🇨🇳
Wang Sizhen, Nanjing, Jiangsu, China
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 650
- Registration Number
- NCT06161025
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, China
🇨🇳Hubei Cancer Hospital, Wuhan, China
🇰🇷National Cancer Center, Goyang-si, Korea, Republic of
Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- National Institute of Cancerología
- Target Recruit Count
- 140
- Registration Number
- NCT06156514
- Locations
- 🇲🇽
National Cancer Institute of Mexico, México, Ciudad De México, Mexico
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 186
- Registration Number
- NCT06139211
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 368
- Registration Number
- NCT06118333
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 100
- Registration Number
- NCT06115499
- Locations
- 🇺🇸
CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸Saint Francis Medical Center, Cape Girardeau, Missouri, United States
🇺🇸Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2023-11-02
- Target Recruit Count
- 88
- Registration Number
- NCT06114004
- Locations
- 🇪🇸
Hospital Universitario de Canarias, Tenerife, Canarias, Spain
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸Hospital Universitario Vall d'Hebron, Barcelona, Spain
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 625
- Registration Number
- NCT06103864
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.